Introduction: Ropivacaine is a local anesthetic widely used for regional anesthesia. One of its advantages is low toxicity at plasma concentrations reached systemically during continuous peripheral or central nervous block. The objective of this study was to test the effect of systemic ropivacaine on pain, hyperalgesia, dynamic allodynia, and flare response. Methods: This randomized, double-blinded, placebo-controlled, crossover study was carried out in at the Clinical Trials Centre, University of Zurich, Switzerland. Twenty healthy male volunteers were included in the study. Exclusion criteria were contraindications or hypersensitivity to local anesthetics, vulnerable subjects (intellectually or mental impaired), drug, alcohol or nicotine abuse, known peripheral neuropathies, diabetes mellitus and/or congestive heart disease. Ropivacaine and saline were infused intravenously during a subcutaneous electrical stimulation. The stimulation software adjusted the stimulus strength according to the rating on a numeric rating scale (NRS; 0-10) maintaining a NRS of 5. Areas of punctate hyperalgesia, dynamic allodynia, and flare response were measured before and after the infusion. Results: The area of hyperalgesia increased significantly with saline (303 ± 380%, P\0.05) and ropivacaine (186 ± 137%, P\0.05). The area of allodynia (253 ± 299%, P\0.05) and flare response (112 ± 24%, P\0.05) increased only during the placebo infusion. Electronic supplementary material The online version of this article (
INTRODUCTION
Local anesthetics play an important role in perioperative analgesia. By means of continuous peripheral or central nerve blocks, they can easily be effective for days with the appropriate management and a minimal risk of toxic effects [1, 2] . Although the plasma concentrations measured after several days of continuous infusion increase considerably, they remain low enough to be tolerated [3] .
A whole body of evidence suggests that not only do local anesthetics prevent the transmission of action potentials at high concentrations (local effect), but also they can modulate pain pathways at low plasma concentrations (systemic effect) [4, 5] . This modulation involves direct interaction of the local anesthetic with neuronal tissue [6] [7] [8] as well as indirect mechanisms via a reduction of circulating pro-inflammatory cytokines [9, 10] .
The pure S-enantiomer ropivacaine is widely used in clinical practice for its safety profile [11, 12] and the lowest potential for neurotoxicity [13] . Recently published data on the effect of low-dose ropivacaine on mechanisms of peripheral neurogenic inflammation concluded that ropivacaine may be useful in the suppression of inflammation, mechanical and visceral hypersensitivity [14, 15] . Some authors even consider ropivacaine to be a promising alternative to systemic lidocaine which is used to treat chronic pain states [16] .
The aim of our study was to quantify the effect of low-dose ropivacaine on hyperalgesia, allodynia, and flare reaction in a model of electrically induced pain in healthy volunteers.
This model allows the study of acute and secondary pain phenomenon evoked by electrical current administered on peripheral nerve endings in the skin. It has been used in earlier investigations to show that local anesthetics can prevent the development of these symptoms [7, 17] . The information gained from this study might be important to evaluate the contribution of systemic ropivacaine in the analgesic/anti-hyperalgesic effect of continuous perineural blocks in clinical practice.
METHODS

Subjects and Study Design
The experimental protocol was approved by the Kantonale Ethikkommission Zürich, Sonneggstrasse 1 ). In the current study, we designed the stimulation protocol in a way to inflict a pain intensity of NRS 5. For example, if the subject indicated on the box a pain intensity value less than 5, the stimulation strength automatically increased in one-percent steps. If the pain intensity was rated more than 5, stimulation strength automatically decreased in onepercent steps. This stimulation approach forced the subjects to rate the pain continuously by means of the box, because the stimulation current was either increasing or decreasing. The rationale of this setup was based on theoretical and practical advantages. First, we wanted to 'optimize' the development of peripheral and central symptoms by Electrical pain was generated by a constant current stimulator on the volar side of one forearm of the study subject. On the other hand, the subjects were rating continuously the intensity of the inflicted pain on a scaled box (0 no pain, 10 maximal pain imaginable) with a sliding button. The box was connected to computer software (QTRACÓ) which adjusted the stimulator output according to the actual rating of the study subject. If the pain rating was below 5, stimulus strength was slowly increased. If the pain rating was more than 5, the stimulus strength slowly decreased. NRS numeric rating scale maintaining a constant intensity of the pain stimulus over time and independent of endogenous suppressing mechanisms which were described with this model [19] . Second, rating a constant pain 'experience' where a study subject only has to decide if the pain intensity is stronger or less strong than a defined value is an easier task than using a full numerical rating scale. As a consequence of this 'pain tracking', the stimulation current was expected to increase over time. Preliminary experiments in four pilot subjects showed that after 20 min of stimulation in all of the subjects, the stimulation current increased more than 40% within the subsequent 30 min (Fig. 2 ). Based on this information, we designed the study and defined two reading points ( After initial adaptation to the painful stimuli, the subjects were asked to rate their pain intensity on the pain tracking box (see Fig. 1 ). The pain tracker forced the subject to maintain a pain intensity of 5 (a). To maintain a constant pain rating level, the current strength has to increase over time due to endogenous pain suppressing mechanisms (b). Before starting the drug infusion at t0, a first sensory testing was performed. Stimulation was restarted and the subjects continued rating the pain. The drug was infused at a constant rate until the current strength of the stimulation reached 140% (t1) of the current strength defined as 100% at t0. Subsequently, the second sensory testing was performed. iv intravenous NRS numeric rating scale
Treatments and Dose Rationale
Administration of systemic ropivacaine is an off-label use of the drug and associated with risks of toxicity [20] . By defining the dosages, particular care was taken to avoid potential dangerous side effects. The calculation was based on previously published data [21] .
The treatment infusions were prepared by an independent non-blinded investigator [22] . Laser Doppler images were recorded before starting the stimulation (baseline image), at the beginning of the infusion (t0) and at the end of the infusion (t1).
Statistical Analysis
The hypothesis of this study was that low-dose ropivacaine may affect clinical signs like hyperalgesia, allodynia and flare reaction (primary endpoints). Secondary endpoints were time to reach the threshold current and incidence of side effects. To our knowledge, no previous study has investigated these endpoints. For our sample size determination, we, therefore, used an approximation based on data previously published on lidocaine [7] . We calculated a SD of 6.9 cm 2 hyperalgesia after 18-min subcutaneous electrical stimulation in a treated and non-treated group. We supposed a mean difference of hyperalgesia of 5.5 cm 2 and calculated a power of 90% for a sample size of 
RESULTS
All 20 subjects included in the investigation finished the study (Fig. 4 ). One subject was not able to clearly indicate hyperalgesia or allodynia in any of the sessions and the data were not included in the analysis. An overview of the demographic of the study population is given in Table 1 . Maintaining a pain intensity of 5 during the stimulation time on the NRS box was considered to be an easy task by all the subjects and was well tolerated. In all the experiments, the targeted threshold of 140% of the stimulus strength at t0 was reached within the infusion time of 30 min (Fig. 5 ). The current strength at t0 was not different between the two groups. There was no time difference in increase to the target threshold between ropivacaine (15.9 ± 7.0 min) and placebo (19.1 ± 5.8 min; P = 0.10).
Hyperalgesia, Allodynia, and Flare Reaction
The areas of hyperalgesia, allodynia, and flare reaction were not different at t0 in the sessions with placebo or ropivacaine. During the infusions of the drugs, the area of hyperalgesia did increase with placebo (303 ± 380%, P\0.05) and ropivacaine (186 ± 137%, P\0.05) (Fig. 6 ).
The area of allodynia increased significantly during the placebo (253 ± 299%, P\0.05)
infusion. We did not find any difference in increase in allodynia during the ropivacaine infusion (137 ± 132%, P = 0.22) between t0 and t1. Similar results were found regarding the flare response. The area and intensity of flare increased significantly during the placebo infusion (area: 112 ± 24%, P\0.05; intensity:
110 ± 17%, P\0.05) but not during the infusion with ropivacaine (area: 107 ± 1%, P = 0.31; intensity: 102 ± 21%, P = 0.19).
Side Effects
In nine subjects, we observed side effects (dizziness and/or tingling around the mouth).
This was significantly higher than during the placebo (n = 0, P\0.01) infusion. Hyperalgesia to mechanical stimuli may develop at the site of injury (zone of primary hyperalgesia) and in the uninjured area surrounding an injury (zone of secondary hyperalgesia) [23] . Primary hyperalgesia involves a sensitization of primary sensory afferents in the periphery which supposedly causes local release of inflammatory mediators [24] . In contrast, 'secondary hyperalgesia' is characterized by increased pain intensity from mechanical stimuli only [25] and is considered to be caused by central mechanisms [26, 27] . As a result, normally painful punctate stimuli become even more painful ('hyperalgesia') and input from normally non-painful stimuli is perceived as painful ('allodynia'). The latter is During the infusion of ropivacaine, the threshold was reached earlier than during the infusion with placebo; however, this difference was not significant. ROPI ropivacaine mediated by low-threshold fibers which are signaling the sensation of touch in normal physiological conditions [28] . The mechanisms are not fully understood but second-order neurons in the central nervous system on the level of the spinal cord play a major role in this process [29] .
DISCUSSION
Peripheral versus Central Effects of Systemic Ropivacaine
On the level of the nerve endings and the receptive field in the skin, local anesthetics interfere with the activation of nociceptors by blocking voltage-gated sodium channels.
This mechanism is mainly responsible for the reduction in acute pain sensation; hence it represents the typical analgesic effect of local anesthetics in the peripheral nervous system [4] .
It is dependent on the concentration of the local anesthetic. In the current study, the concentration reached systemically was probably too low to show any analgesic effect on the painful stimulation. This is in line with previous investigations of low-dose local anesthetics where in healthy volunteers also acute nociception remained intact in the presence of a limited and selective antihyperalgesic effect of lidocaine [17, 30] .
However, the flare reaction, a typical peripheral symptom of the electrical stimulation [26] , was significantly modulated when activated. The most likely explanation for a diminished flare response in the presence of local anesthetics is an attenuation of a vascular response to bradykinin and substance P not only when applied locally, but also when applied systemically at low-dose concentrations [14] . Also, local anesthetics tend to cause vasoconstriction which has to be taken into consideration when interpreting flare response [31] . It is postulated that the degree of vasoconstriction depends on the stereoselectivity of the local anesthetic and, therefore, S-enantiomers like ropivacaine could have a more pronounced effect than the other local anesthetics [32] . The current study revealed that the flare response was diminished by ropivacaine in terms of area and intensity and, therefore, the results go in line with previous investigations with different systemic sodium channel blockers [7, 14, 17, 33] .
Another possible peripheral effect we observed was the diminished development of allodynia. There is abundant evidence that large myelinated fibers are involved in mediating pain in the area of secondary hyperalgesia [34] and allodynia [35] . Low-dose local anesthetics can prevent flow of information (number of action potentials) toward the central nervous system, especially in neuropathic nerves [36] . As a consequence, less neurotransmitter will be released at the central endings in the spinal cord, and nociceptive activity in the dorsal horn will decrease [37] . This diminished activity in the dorsal horn, in turn, will lead to a decrease of 'secondary hyperalgesia' or allodynia on the peripheral end of the nociceptors in the surrounding tissue of the receptive field [6] [7] [8] .
There are still no clear neurophysiological investigations as to what the exact underlying mechanisms of brush-evoked allodynia are, but an involvement of the central nervous system is undisputed [29] . Therefore, the results of this study would imply that ropivacaine modulated pain pathways also on a central level. Regarding the impact on mechanical hyperalgesia, Hahnenkamp et al. [38] found that Sropivacaine had a larger effect on the inhibition of N-methyl-D-aspartate receptor (also known as the NMDA receptor compared to other local anesthetics. This inhibition would imply an even stronger effect on secondary hyperalgesia, hence on central mechanisms) [38] . The results of this study, however, showed that ropivacaine did not impair the development of punctate hyperalgesia. Since our sensory testing did not differentiate between primary (peripheral mechanisms) and secondary hyperalgesia (central mechanisms), the diminished sensitization processes in the periphery-indirectly illustrated by the impaired flare response-would account solely for an incomplete explanation of the lacking efficacy. Our findings, however, are comparable to a recent publication by Charlet et al. [39] .
They found that systemic ropivacaine did not prevent mechanical hyperalgesia compared to locally applied ropivacaine without giving a satisfying explanation of the underlying mechanisms [39] .
There is no clear hypothesis as to why ropivacaine would act differently to other sodium channel blockers in terms of central mechanisms. In this study, despite observing a reduced development of punctate hyperalgesia compared to placebo, we assume that the concentrations reached intrathecally were not high enough and/or the variance of the electrical model to induce hyperalgesia was too large to detect statistical significant effects.
CONCLUSION
The results of this study imply that systemic ropivacaine may prevent pain sensitization processes. Clinically, these effects could be relevant since continuous application of ropivacaine (e.g., continuous nerve block after surgery) leads to substantially elevated systemic plasma concentration. The incidence of side effects was nearly 50% during the infusion with ropivacaine at even low dosages. Therefore, the therapeutic benefit to justify an intravenous use of the drug to treat chronic pain states-as it was proposed by other groups [16] -seems to be very limited. Furthermore, the extrapolation of results in this study with healthy volunteers on neuropathic pain states in patients needs to be verified in a clinical setting. Therefore, more studies with different models of hyperalgesia (e.g., UV model or capsaicin model) and in patients with neuropathic pain are needed. 
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